These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 28532194

  • 1. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V, Foo J, Ahir H, Sarpong E, Merchant S.
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
    Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A.
    BMC Infect Dis; 2017 Apr 28; 17(1):314. PubMed ID: 28454524
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States.
    Prabhu VS, Solomkin JS, Medic G, Foo J, Borse RH, Kauf T, Miller B, Sen SS, Basu A.
    Antimicrob Resist Infect Control; 2017 Apr 28; 6():107. PubMed ID: 29090091
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T, Eckmann C, Bassetti M, Tichy E, Di Virgilio R, Baillon-Plot N, Charbonneau C.
    Antimicrob Resist Infect Control; 2019 Apr 28; 8():204. PubMed ID: 31890160
    [Abstract] [Full Text] [Related]

  • 5. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C.
    Clin Infect Dis; 2015 May 15; 60(10):1462-71. PubMed ID: 25670823
    [Abstract] [Full Text] [Related]

  • 6. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C, Solomkin J.
    Expert Opin Pharmacother; 2015 Feb 15; 16(2):271-80. PubMed ID: 25529765
    [Abstract] [Full Text] [Related]

  • 7. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
    Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G.
    Appl Health Econ Health Policy; 2015 Aug 15; 13(4):369-79. PubMed ID: 25761545
    [Abstract] [Full Text] [Related]

  • 8. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW, Long J, Huntington JA.
    BMC Infect Dis; 2017 May 02; 17(1):316. PubMed ID: 28464828
    [Abstract] [Full Text] [Related]

  • 9. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan 02; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 10. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
    Chen GJ, Pan SC, Foo J, Morel C, Chen WT, Wang JT.
    J Microbiol Immunol Infect; 2019 Oct 02; 52(5):807-815. PubMed ID: 31029529
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
    Jansen JP, Kumar R, Carmeli Y.
    Value Health; 2009 Oct 02; 12(2):234-44. PubMed ID: 20667059
    [Abstract] [Full Text] [Related]

  • 12. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
    Paladino JA, Gilliland-Johnson KK, Adelman MH, Cohn SM.
    Surg Infect (Larchmt); 2008 Jun 02; 9(3):325-33. PubMed ID: 18570574
    [Abstract] [Full Text] [Related]

  • 13. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
    Armstrong ES, Farrell DJ, Palchak M, Steenbergen JN.
    Antimicrob Agents Chemother; 2016 Jan 02; 60(1):666-8. PubMed ID: 26552971
    [Abstract] [Full Text] [Related]

  • 14. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
    Scott LJ.
    Drugs; 2016 Feb 02; 76(2):231-42. PubMed ID: 26746849
    [Abstract] [Full Text] [Related]

  • 15. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
    Jansen JP, Kumar R, Carmeli Y.
    Pharmacoeconomics; 2009 Feb 02; 27(12):1045-56. PubMed ID: 19908928
    [Abstract] [Full Text] [Related]

  • 16. Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
    Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J.
    Antimicrob Agents Chemother; 2016 Jul 02; 60(7):4387-90. PubMed ID: 27139477
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
    Mikamo H, Monden K, Miyasaka Y, Horiuchi T, Fujimoto G, Fukuhara T, Yoshinari T, Rhee EG, Shizuya T.
    J Infect Chemother; 2019 Feb 02; 25(2):111-116. PubMed ID: 30528561
    [Abstract] [Full Text] [Related]

  • 18. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):900-905. PubMed ID: 27999024
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS.
    J Antimicrob Chemother; 2017 Jan 01; 72(1):268-272. PubMed ID: 27707990
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ, Chahine EB, Cogan P, Fete M.
    Ann Pharmacother; 2015 Sep 01; 49(9):1046-56. PubMed ID: 26160970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.